COR-L23 Xenograft Model Service for Large Cell Carcinoma

The COR-L23 xenograft model serves as a robust preclinical platform for large cell lung carcinoma, enabling researchers to evaluate therapeutic efficacy, tumor growth kinetics, and pharmacodynamic responses in an immunocompromised host environment. At Alfa Cytology, we specialize in building clinically relevant preclinical tumor models that mirror the aggressive biology of large cell lung carcinoma. Our COR-L23 xenograft service integrates meticulous cell line authentication, standardized inoculation protocols, and longitudinal tumor monitoring to deliver reproducible datasets that inform early-stage drug development decisions—from candidate screening to combination regimen exploration.

Overview of COR-L23 Xenograft Model for Large Cell Carcinoma

Large cell carcinoma (LCC) of the lung represents a diagnostically challenging subset of non-small cell lung cancer (NSCLC) characterized by sheets of pleomorphic cells lacking glandular, squamous, or neuroendocrine differentiation. Under the 2015 WHO classification, 'pure' LCC has become increasingly rare as immunohistochemical and molecular profiling reassigns many cases to adenocarcinoma or squamous cell carcinoma subtypes. Nevertheless, LCC retains clinical significance as an aggressive, poorly differentiated neoplasm with limited therapeutic options and a propensity for early metastatic spread. The COR-L23 cell line, originally isolated from the pleural effusion of a patient with giant cell anaplastic carcinoma, captures the undifferentiated, highly tumorigenic nature of this disease entity, making it a valuable surrogate for preclinical investigation.

Fig 1. FZ-AD005 showed potent, DLL3-dependent cytotoxicity against DMS 53 SCLC cells in vitro (IC50 0.152–4.295 nmol/L), supporting the selection of DMS 53 as a CDX xenograft model for preclinical evaluation of DLL3-targeted ADCs. (Guo, Qingsong, et al., 2024)

Xenograft models established with COR-L23 cells recapitulate several hallmarks of large cell lung carcinoma, including rapid tumor establishment, aneuploid karyotype, and sensitivity to agents targeting KRAS-driven signaling networks. The cell line harbors a homozygous KRAS p.Gly12Val mutation together with c-MYC amplification and TP53 alterations, molecular signatures that converge on proliferative and survival pathways commonly dysregulated in NSCLC. When implanted subcutaneously or orthotopically into immunodeficient mice, COR-L23 cells form progressively growing tumors that permit serial caliper measurements, non-invasive imaging, and post-mortem histopathological analysis. These models support a spectrum of preclinical endpoints, including tumor growth inhibition, survival benefit, biomarker modulation, and toxicity profiling, thereby bridging the gap between in vitro cytotoxicity assays and later-stage translational studies.

Cell Line Information: COR-L23

The COR-L23 cell line was established in 1985 from the pleural effusion of a 62-year-old Caucasian male diagnosed with giant cell anaplastic carcinoma of the lung. These adherent epithelial cells exhibit a polygonal morphology with very large, often multinucleate configurations, and display a population doubling time of approximately 30 hours under standard culture conditions. The line is tumorigenic in nude mice and has been extensively utilized in drug resistance, cytotoxicity, and interferon response studies. Several derivative sublines have been generated, including multidrug-resistant (COR-L23/R), cisplatin-resistant (COR-L23/CPR), and revertant (COR-L23/R23-) variants, expanding the experimental versatility of this model system. The following table summarizes the key characteristics of the parental COR-L23 cell line.

Our Services

Alfa Cytology offers a comprehensive COR-L23 xenograft model service tailored to the demands of large cell lung carcinoma drug discovery. From cell line expansion and quality control to tumor implantation, in-life monitoring, and terminal necropsy with histopathology, every stage of the workflow is executed under rigorously controlled conditions. Our team ensures that each study is powered with appropriate group sizes, randomization, and blinding strategies to maximize scientific rigor and regulatory acceptability for IND-enabling packages.

Workflow of COR-L23 Xenograft Model Construction

Construction of a reliable COR-L23 xenograft model requires systematic coordination of cell culture logistics, animal husbandry, surgical technique, and data acquisition. The workflow described below outlines the critical stages from master cell bank qualification through to study completion and reporting, ensuring traceability and reproducibility at every step.

1. Cell Line Resuscitation and Expansion: A working cell bank vial is thawed under controlled conditions and expanded in RPMI 1640 medium supplemented with 10% FBS. Cells are passaged for two to three generations to ensure viability and exponential growth prior to harvest for implantation. Mycoplasma testing and STR profiling are performed to confirm identity and sterility.
2. Pre-Implantation Cell Preparation: On the day of inoculation, COR-L23 cells are harvested during log-phase growth using trypsin/EDTA, washed in sterile PBS, and resuspended at the desired concentration—typically 5–10 × 10⁶ cells per 100–200 µL of serum-free medium mixed with Matrigel or an equivalent basement membrane matrix to enhance engraftment efficiency. Cell viability is verified by trypan blue exclusion and must exceed 95%.
3. Animal Preparation and Implantation: Immunodeficient mice (commonly NOD-SCID or nude mice, 6–8 weeks of age) are acclimatized for at least five days. For subcutaneous models, cells are injected into the right flank using a sterile 25-gauge needle. For orthotopic delivery, cells are introduced via intrathoracic injection or thoracotomy-guided direct lung parenchymal implantation under anesthesia.
4. Tumor Monitoring and Caliper Measurements: Tumor dimensions are recorded twice weekly using digital calipers, and tumor volume is calculated with the modified ellipsoid formula (length × width² × 0.5). Mice are weighed concurrently to detect systemic toxicity. Tumor growth curves are plotted for each cohort, with randomization performed once tumors reach a palpable size of approximately 50–100 mm³.
5. Dosing and Pharmacodynamic Sampling: Test articles are administered according to the study protocol—via oral gavage, intraperitoneal, intravenous, or subcutaneous routes—once tumors have established. Blood samples may be collected via retro-orbital bleeding or tail vein nick for pharmacokinetic analysis. Tumor biopsies or whole tumors are harvested at predefined time points for downstream molecular and histological evaluation.
6. Terminal Procedures and Necropsy: At study endpoint—defined by tumor burden limits, predetermined study duration, or complete response—mice are humanely euthanized. A full necropsy is performed to collect tumors, lungs, liver, spleen, kidneys, and other tissues of interest. Tissues are fixed in 10% neutral buffered formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin for histopathological assessment.
7. Data Analysis and Reporting: Tumor growth inhibition (TGI) is calculated relative to vehicle-treated controls. Kaplan-Meier survival curves are generated where applicable. Immunohistochemical staining for Ki-67, cleaved caspase-3, p-ERK, or client-specified targets is quantified by digital image analysis. All raw data, statistical outputs, and representative images are compiled into a comprehensive study report with methodology, results, and interpretation sections.

Fig 2. COR-L23 xenograft model construction workflow.

Case Study-COR-L23 Xenograft Model Development

In a recent preclinical engagement, Alfa Cytology established a subcutaneous COR-L23 xenograft model to evaluate the anti-tumor activity of a novel small-molecule inhibitor targeting the MAPK signaling axis. Following successful cell line authentication and expansion, COR-L23 cells were inoculated into NOD-SCID mice at a density of 1 × 10⁷ cells per animal. Palpable tumors emerged within 10–14 days, with median starting volumes of approximately 75 mm³ at the time of randomization. Mice were stratified into vehicle control and treatment cohorts, with compound administration initiated on a twice-daily schedule. Tumor volumes and body weights were monitored biweekly throughout the dosing phase. At study termination, tumors and major organs were harvested for histopathological and biomarker analysis. Pharmacodynamic evaluation revealed dose-dependent modulation of downstream effector proteins, and hematoxylin-eosin staining confirmed intact tumor architecture with areas of necrosis correlating to treatment response. These preclinical findings provided critical proof-of-concept data to support further optimization of the candidate compound.

Why Choose Alfa Cytology?

Selecting the right CRO partner for your xenograft program can determine whether preclinical data translates into actionable development decisions. Alfa Cytology distinguishes itself through technical depth, operational transparency, and an unwavering commitment to data integrity. Below are the core reasons sponsors trust us with their COR-L23 xenograft studies.

• Rigorous cell line stewardship with STR authentication, mycoplasma screening, and low-passage working banks to minimize genetic drift.
• Flexible study designs accommodating subcutaneous, orthotopic, and patient-derived xenograft formats with customized endpoints.
• Real-time tumor monitoring via digital calipers and optional non-invasive imaging modalities such as MRI or bioluminescence.
• Integrated pharmacodynamic and pharmacokinetic sampling to correlate drug exposure with target engagement and biological effect.
• GLP-compliant histopathology and immunohistochemistry services with quantitative digital pathology readouts.
• Dedicated project managers providing weekly progress updates, raw data transparency, and adaptive protocol amendments when scientific needs evolve.
• Competitive timelines with study initiation typically within 3–4 weeks of contract execution, accelerating your path to IND-enabling milestones.

Contact Us

Whether you are initiating a first-in-class screening campaign or refining the dosing schedule of a late-lead candidate, Alfa Cytology is ready to support your large cell lung carcinoma program with a validated COR-L23 xenograft platform. Reach out to us today to discuss your specific study requirements, receive a tailored proposal, and discover how our preclinical expertise can de-risk your therapeutic development pipeline.

To get started, simply contact us through our inquiry form or email our business development team directly. We look forward to collaborating with you on your next preclinical oncology study.

For research use only. Not intended for any clinical use.